Focus on tolerability
Insurance is a coin flip: some private plans cover obesity, public plans mostly dont
Only remove the plastic flip-off cap, then cleanse the exposed rubber stopper with alcohol before each use
As an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, retatrutide shares the gastrointestinal side effect profile characteristic of the broader incretin-based drug class
Anticipated Costs Post-Approval While neither compound has reached market, pricing for similar medications provides context: Semaglutide (Wegovy) Approximately $1,300-$1,500 monthly without insurance Tirzepatide (Zepbound) Approximately $1,000-$1,200 monthly without insurance Cagrilintide and retatrutide would likely fall in similar price ranges, with combination therapy potentially costing $2,000-$3,000 monthly without insurance coverage
This makes GLP-1 peptides an effective option for those struggling with obesity and weight-related health issues
